Recent Company News

• 09:00 AM ET Nov 04, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:24 PM ET Oct 27, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:51 PM ET Nov 03, 2025
  

  Follow-up: U.S. FDA approves KYGEVVI as treatment for TK2d in adults and pediatric patients; availability and RPDPRV voucher status (€220.00, 0.00)

• 12:59 PM ET Nov 03, 2025
  

  FDA issues press release highlighting first drug approval for rare disease TK2d (€220.00, 0.00)

• 12:31 AM ET Nov 03, 2025
  

  Goldman Sachs makes changes to European Conviction List - Directors' Cut

• 01:04 PM ET Oct 31, 2025
  

  UCB announces BIMZELX (bimekizumab-bkzx) data in hidradenitis suppurativa showed improvements in pain and resolution of draining tunnels sustained to three years (€222.50, 0.00)

• 02:09 AM ET Oct 29, 2025
  

  UCB to unveil new data for RYSTIGGO and ZILBRYSQ for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session (€227.20, 0.00)

• 05:18 AM ET Oct 27, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 12:37 AM ET Oct 27, 2025
  

  Jefferies transfers AZN.LN, GSK.LN, NOVN.SW, others